Pharmaceutical Technology17 天
Golidocitinib by Dizal Pharmaceutical for Sezary Syndrome: Likelihood of Approval
Golidocitinib (DZD-4205) is under development for the treatment of non-small cell lung cancer and T cell lymphomas including peripheral T cell lymphoma, vascular immunoblast type (AITL), Anaplastic ...
Pharmaceutical Technology17 天
Golidocitinib by Dizal Pharmaceutical for Cutaneous T-Cell Lymphoma: Likelihood of Approval
Golidocitinib (DZD-4205) is under development for the treatment of non-small cell lung cancer and T cell lymphomas including peripheral T cell lymphoma, vascular immunoblast type (AITL), Anaplastic ...